Association of the Cumulative Dose of Radioactive Iodine Therapy With Overall Survival in Patients With Differentiated Thyroid Cancer and Pulmonary Metastases

Association of the Cumulative Dose of Radioactive Iodine Therapy With Overall Survival in Patients With Differentiated Thyroid Cancer and Pulmonary Metastases

Purpose: The optimal cumulative dose of radioactive iodine therapy (RAIT) for patients with differentiated thyroid cancer (DTC) and pulmonary metastases (PM) is not known, therefore we evaluated the association between the cumulative dose of RAIT and overall survival (OS).Methods: A total of 202 pat...

Full description

Bibliographic Details
Main Authors:	Jing Yang, Rong Zheng, Meng Liang, Yingying Jia, Lin Lin, Jianhua Geng, Shengzu Chen, Ye-Xiong Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-06-01
Series:	Frontiers in Oncology
Subjects:	differentiated thyroid cancer pulmonary metastases radioiodine therapy cumulative dose patient age
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2019.00558/full

Similar Items

Outcomes following I-131 treatment with cumulative dose exceeding or equal to 600 mCi in differentiated thyroid carcinoma patients
by: Chalermrat Kaewput, et al.
Published: (2021-01-01)

Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b)
by: Pedro Weslley Rosario, et al.
Published: (2017-02-01)

Radioiodine-resistant metastases of well-differentiated thyroid cancer, analysis of tumor characteristics and primary surgical intervention
by: M. V. Ostafiychuk, et al.
Published: (2021-10-01)

A rare case of minimally invasive follicular thyroid cancer with intraluminal superior vena cava and right atrium metastases
by: Alex Cheen Hoe Khoo, et al.
Published: (2019-01-01)

Lung Metastases From Papillary Thyroid Cancer With Persistently Negative Thyroglobulin and Elevated Thyroglobulin Antibody Levels During Radioactive Iodine Treatment and Follow-Up: Long-Term Outcomes and Prognostic Indicators
by: Zhong-Ling Qiu, et al.
Published: (2020-01-01)

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY
by: P. O. Rumyantsev, et al.
Published: (2015-04-01)

Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
by: Shirlei Kugler Aiçar Súss, et al.
Published: (2018-04-01)

Failure of iodine uptake in microscopic pulmonary metastases after recombinant human thyroid-stimulating hormone stimulation
by: Courtney Lawhn-Heath, et al.
Published: (2020-01-01)

CYTOLOGICAL CHARACTERISTICS OF POSTOPERATIVE METASTASES OF PAPILLARY THYROID CANCER DURING THE DEVELOPMENT OF SECONDARY RADIOIODINE REFRACTORINESS
by: Anna Zelinskaya, et al.
Published: (2020-01-01)

Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma
by: Arwa Alsaud, et al.
Published: (2020-03-01)

Case report<Br>Graves’ thyrotoxicosis in a patient with metastatic differentiated thyroid carcinoma and chronic lymphocytic leukaemia (CLL)
by: Jacek Makarewicz, et al.
Published: (2007-06-01)

Papillary thyroid cancer recurrence 43 Years following Total Thyroidectomy and radioactive iodine ablation: a case report
by: Yaw Amoako-Tuffour, et al.
Published: (2017-10-01)

Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up
by: Zhong-Ling Qiu, et al.
Published: (2021-02-01)

Investigation of post-therapeutic image-based thyroid dosimetry using quantitative SPECT/CT, iodine biokinetics, and the MIRD’s voxel S values in Graves’ disease
by: Naotoshi Fujita, et al.
Published: (2020-01-01)

Efficacy of Low-Dose Radioiodine Ablation in Low- and Intermediate-Risk Differentiated Thyroid Cancer: A Retrospective Comparative Analysis
by: Ana María Gómez-Pérez, et al.
Published: (2020-02-01)

Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases
by: Jochen Hammes, et al.
Published: (2018-12-01)

Measurement of radiation doses absorbed in the thyroid cancer when treated with radioactive iodine 131I
by: Asema Mahmood Alemam
Published: (2013-06-01)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
by: Cristiane J. Gomes-Lima, et al.
Published: (2021-02-01)

Radionuklidna terapija bolesnika sa regionalnim i udaljenim metastazama diferenciranog karcinoma štitaste žlezde
by: Mihailović Jasna
Published: (2011-01-01)

A rare case of lingual thyroid with hyperthyroidism: A case report and review of the literature
by: Mattakarottu Joseph Jacob, et al.
Published: (2012-01-01)

Determination of Organ Doses in Radioiodine Therapy using Monte Carlo Simulation
by: Daryoush Shahbazi-Gahrouei, et al.
Published: (2015-01-01)

Measurement of Radiation Exposure to Caregivers of Patients with Thyroid Diseases Treated with Iodine-131: A Review
by: Ali Abdulhasan Kadhim, et al.
Published: (2020-09-01)

Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer
by: Zhong-Ling Qiu, et al.
Published: (2018-07-01)

Outcomes of patients with bone metastases from differentiated thyroid cancer
by: Inés Califano, et al.

Original paper<br>Effects of absorbed dose of 131I isotope on the effectiveness of ablation of thyroid remnant tissue
by: Zbigniew Adamczewski, et al.
Published: (2007-06-01)

Concept of cumulative dose in Ayurveda with special reference to metallic Bhasma
by: Pravin Jawanjal, et al.
Published: (2020-01-01)

The diagnostic challenge of coexistent sarcoidosis and thyroid cancer – a retrospective study
by: Vera Wenter, et al.
Published: (2021-02-01)

Thyroid carcinoma in woman. gynecologist view
by: Т. Ф. Татарчук, et al.
Published: (2019-06-01)

Occurrence of symptomatic meningioma as a second neoplasm in patients with differentiated thyroid cancer treated with radioiodine
by: Nishikant Avinash Damle, et al.
Published: (2012-01-01)

Seeking optimal management for radioactive iodine therapy-induced adverse effects
by: Andreas Charalambous
Published: (2017-01-01)

Evaluation of Thyroid to Background Ratios in Hyperthyroid Cats
by: Bettencourt, Ann Elizabeth
Published: (2014)

Papillary carcinoma thyroid with rare metastases: A case report and review
by: Ramya Yethadka, et al.
Published: (2016-12-01)

Evaluation of Discordance in Differentiated Thyroid Cancer Patients with Negative Radioiodine Scans and Positive Thyroglobulin Values at the Ablation Outcome Control
by: Zeynep Gözde Özkan, et al.
Published: (2012-03-01)

Sudden Development of Subcutaneous Nodules Shortly after Radioiodine Treatment for Thyroid Cancer Caused by Self-Limiting Sarcoidosis
by: Wael Zaher, et al.
Published: (2020-05-01)

Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer
by: Lv RB, et al.
Published: (2017-08-01)

Comparison of radioiodine ablation rates between low versus high dose, and according to the surgeon's expertise in the low-risk group of differentiated thyroid cancer
by: Ghazal Norouzi, et al.
Published: (2021-01-01)

Papillary thyroid microcarcinoma
by: V A Smirnova, et al.
Published: (2015-06-01)

Pre-Therapeutic Measurements of Iodine Avidity in Papillary and Poorly Differentiated Thyroid Cancer Reveal Associations with Thyroglobulin Expression, Histological Variants and Ki-67 Index
by: Joachim N. Nilsson, et al.
Published: (2021-07-01)

Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?
by: Elizabeth J. de Koster, et al.
Published: (2021-03-01)

Empiric Therapy with Low-Dose I-131 in Differentiated Cancer Thyroid: What is the Magic Number?
by: Ajit S Shinto, et al.
Published: (2013-01-01)

Cannot write session to /tmp/vufind_sessions/sess_uh5u9qna2kkq147cr0bbh3epge